LianBio Assigns Development and Commercialization Rights for NBTXR3 in Asia to Janssen

Nanobiotix, a late-stage clinical biotechnology company, announced on Tuesday that its partner LianBio has entered into an agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company. Under the terms of this agreement, LianBio is assigning its exclusive rights to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand to Janssen.

NBTXR3 is a first-in-class radioenhancer developed by Nanobiotix. It is administered via a single injection into a tumor and activated by radiotherapy, aiming to increase tumor cell destruction. The drug is currently being evaluated in clinical trials, including a Phase 3 study for head and neck cancers.

The transaction consolidates global development and commercialization rights for NBTXR3 under Janssen. Nanobiotix is eligible to receive up to an aggregate of $220 million in potential contingent milestone payments, along with tiered, low double-digit royalties on net sales in the Asian territories, according to previously agreed economic terms.

LianBio will support the transition of the asset to Janssen for a period not exceeding six months. Nanobiotix stated its continued focus on global registration for NBTXR3.